Myelodysplastic Syndrome

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

By

A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

By

Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.

MDS, AML a Risk With PARP Inhibitors in <i>BRCA</i> Mutation Carriers

MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers

By

What is the concern behind PARP inhibitors and leukemia?

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

By

Research on the transformation of MDS to AML identifies a protein whose deletion is a potential tumor suppressor that would block this disease progression.

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

By

Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

By

Azathioprine for the treatment of autoimmune disorders is significantly associated with an increased risk of acute myeloid leukemia and myelodysplastic syndromes.

End-of-life Care Intensity for Patients With MDS May Be Suboptimal

By

The intensity of end-of-life care for patients with myelodysplastic syndromes may be optimal in terms of hospice use, a recently published study has shown.

Darbepoetin Alfa Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome

By

Darbepoetin alfa reduced the incidence of red blood cell transfusions in anemic patients with low and intermediate-1 risk myelodysplastic syndrome, according to phase 3 clinical trial data.

Molecular Signature Predicts Transition from Myelodysplastic Syndrome to Acute Myeloid Leukemia

By

Progress from myelodysplastic syndrome to AML is linked to the enzyme glycogen synthase kinase, and a molecular signature is found to predict clinical outcomes of patients with MDS.

Pretransplant Myeloablative Regimens Confirmed Standard of Care for MDS, AML

Pretransplant Myeloablative Regimens Confirmed Standard of Care for MDS, AML

By

Results of a phase 3 randomized trial support high intensity conditioning with myeloablative regimens prior to allogeneic stem cell transplantation as standard of care for patients with acute myeloid leukemia.

Among Medicare Beneficiaries with MDS, No Association Between Costs of Care, Overall Survival

Among Medicare Beneficiaries with MDS, No Association Between Costs of Care, Overall Survival

By

Overall survival rates for Medicare beneficiaries with myelodysplastic syndrome (MDS) showed little difference related to disease-related costs, according to data presented at the 2015 ASH Annual Meeting in Florida.

Early discharge after intensive AML, MDS chemo can reduce costs, antibiotics use

Early discharge after intensive AML, MDS chemo can reduce costs, antibiotics use

Early discharge after intensive acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) can reduce both costs and use of intravenous antibiotics, according to a new study.

Combination therapy effective for patients with higher-risk myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)

Combination therapy effective for patients with higher-risk myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)

By

Combined treatment with azacitidine and lenalidomide may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.

Age alone should not limit access to stem cell transplants for patients with MDS

By

Patients with myelodysplastic syndrome age 66 to 74 years did as well with stem cell transplantation as patients age 60 to 65 years. This research was presented at the 2013 ASH Annual Meeting, in New Orleans.

Anemia in patients with MDS

Anemia in patients with MDS

By

Managing anemia in patients with myelodysplastic syndrome (MDS) is complex. When are erythroid growth factors used as primary treatment?

Withdrawn leukemia drug has good results in UK study

Gemtuzumab ozogamicin, discontinued here in 2010, reduced relapse risk and improved survival in Welsh patients with acute myeloid leukemia.

HIV drug can prevent complications after stem-cell transplant

An HIV drug helped lower the risk of graft-versus-host disease in persons with blood cancer who had stem-cell transplants to rebuild bone marrow.

FDA Update: May/June 2012

Drug Safety Communication on lenalidomide (Revlimid); FDA approval for pazopanib (Votrient)

Specific Mutations in AML Affect Response to Therapy

Specific Mutations in AML Affect Response to Therapy

Also, bone marrow cells in myelodysplastic syndromes, secondary AML are clonal.

Comparable Clinical Activity for Low-, High-Dose Clofarabine

Comparable Clinical Activity for Low-, High-Dose Clofarabine

More adverse effects seen for high dose in patients with higher-risk myelodysplastic syndrome

Myelodysplasia gene mutation can aid diagnosis

The recent discovery of gene mutations in a genomic study of myelodysplastic syndromes could enable diagnosis using only a blood test rather than a bone marrow biopsy.

Family studies reveal leukemia gene

A genetic defect found on the GATA2 gene predisposes people to acute myeloid leukemia (AML) and myelodysplasia, researchers have learned.

Case 3: Iron Overload Increasingly is a Concern in Patients with Myelodysplastic Syndrome

Supportive care and symptom management traditionally have been the focus of treatment for patients with myelodysplastic syndrome (MDS). Recent advances in therapeutic modalities, however, have increased the lifespan of patients with MDS, who are now receiving red blood cell transfusions for their chronic anemia, resulting in iron overload. This case looks at a 71-year-old man who received a bone marrow biopsy, which found dysplasia and ringed sideroblasts but no myeloid blasts.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs